Table 4.

Reported taxane skin testing protocols

Reference	Agent	SPT dilutions (mg/mL)	IDT dilutions (mg/mL)	No. of patients with ST	SPT positive	IDT positive
Picard et al. (2016) [32]	Paclitaxel	1	0.001, 0.01	138	5 (4%)	92 (67%)
	Docetaxel	0.4	0.04, 0.4	9	0	8 (89%)
Pagani et al. (2019) [19]	Paclitaxel	6	0.06	63	0	10 (16%)
	Docetaxel	1	0.01	21	0	4 (19%)

Published skin testing dilutions for skin prick and corresponding intradermal tests from the two largest studies are shown. Protocols have not been compared for different patient characteristics. There were more patients with ovarian cancer and prostate cancer in Picard et al. [32], while breast cancer was the most common cancer in Pagani et al. [19]